Browse News

Found 27 articles

• Human Microbiome Market Size Worth $2.92Bn by 2028 at 22.2% CAGR Led by Probiotics Products (24.71% Market Share in 2021) Global Analysis by The Insight Partners

  5/30/2023

  The Insight Partners published latest research study on "Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs and Supplements)

• Human Microbiome Market Growth (22.2% CAGR) Led by Probiotics Segment Held Market Share of 24.71% in 2021: The Insight Partners

  4/18/2023

  The Insight Partners published latest research report on "Human Microbiome Market Size Report, Scope, Trends, Revenue, Share Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Disease, Application and Geography,"

• Key patent issued on Eligo's gene editing breakthroughs applied to skin disorders

  11/15/2022

  Eligo Bioscience today announced the issuance by the US Patent and Trademark Office (USPTO) of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support therapeutic interventions in multiple serious skin disorders.

• 

  FDA Review: Phanes, Pfizer, GSK and More

  10/14/2022

  The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions.  

• Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine

  10/11/2022

  Eligo Bioscience, a leading in vivo gene-editing company, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation for its oral drug candidate EB003.

• Eligo Bioscience further strengthens its position as leader in the field of gene editing of the microbiome with additional landmark CRISPR patent

  10/3/2022

  Eligo Bioscience announced the issuance by the US Patent and Trademark Office of an additional landmark patent that further strengthens Eligo's dominant position in the field of CRISPR-based killing of bacteria.

• Eligo Bioscience and Kantonsspital St. Gallen announce their strategic alliance to address inflammatory cardiac diseases through in vivo gene editing

  9/13/2022

  Eligo Bioscience, a gene editing company, and Kantonsspital St. Gallen, one of Switzerland's leading hospitals, announced today their strategic alliance to develop a gene editing therapy for inflammatory cardiac diseases induced by bacterial mimicry.

• Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and presents first-ever animal data at CRISPR 2022 Conference

  6/29/2022

  Eligo Bioscience, a gene editing company, announced today that it has been granted the first patents covering in situ base editing of the microbiome.

• 

  Gene-Editing the Microbiome: The Limitless Possibilities

  6/2/2022

  Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.

• LatchBio Raises $28M Series A to Bring a Modern Data Analysis Stack to Biologists

  6/2/2022

  Company’s web-based platform empowers researchers to integrate, process, and visualize biological data in one place, shortening timelines from experiment to results.

• Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome on CRISPR-Cas antimicrobials

  12/2/2021

  Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021 , a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to The Rockefeller University.

• Human Microbiome Market Growing at a CAGR of 23.6% During 2021 to 2027 | COVID-19 Impact and Global Analysis by The Insight Partners

  8/20/2021

  The human microbiome market is expected to reach US$ 1,873.53 million in 2027 from US$ 356.29 million in 2019. The market is estimated to grow at a CAGR of 23.6% from 2020 to 2027.

• Human Microbiome Market expected to reach US$ 1,873.53 million in 2027, says The Insight Partners

  6/1/2021

  On the other hand, strict government guidelines and lack of knowledge about detailed examination are likely to have a negative impact on the growth of the market in the coming years.

• Eligo inks deal with GSK potentially worth up to $224M

  1/11/2021

  Eligo Bioscience SA announced that it has entered into a research and option agreement with GlaxoSmithKline aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation.

• Seventure Partners Life Sciences Corporate Update Health for Life: July 2019 – September 2019

  10/10/2019

  Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period July 2019 to September 2019.

• Seventure Partners Announces First Close of New Fund, Sport & Performance Capital

  7/5/2019

  Seventure Partners, one of Europe’s leaders in financing innovation in Life sciences and associated industries, announces the launch of Sport & Performance Capital™, a new fund dedicated to supporting innovation in the sport and wellness industries. With a final target of €80 million, the venture fund will invest in startup companies and growing SMEs furthering physical activity to help promote health and physical fitness.

• Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

  3/5/2019

  Under the leadership of Isabelle de Cremoux, Health for Life Capital II™ builds upon its world-renowned experience in the microbiome field and its success with its first Health for Life Capital™ fund

• Seventure Partners Life Sciences Corporate Update September 2018 – February 2019

  3/1/2019

  Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, is pleased to provide an update on its life science investments for the period September 2018 to February 2019.

• Seventure Partners Life Sciences Investing Update - H2 2017

  1/11/2018

  Seventure Partners today announces its corporate update for July - December 2017.

• Seventure Partners' Microbiome Portfolio is Reaching Critical Milestones in Current and Upcoming Clinical Trials

  12/14/2017

  Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, is seeing rapid progress from innovation into human trials, with five of its portfolio companies advancing their human microbiome products with varying modalities and therapeutics targets in clinical trials.